Literature DB >> 487698

Tobramycin pharmacokinetics in morbidly obese patients.

R A Blouin, H J Mann, W O Griffen, L A Bauer, K E Record.   

Abstract

Tobramycin kinetics were examined in 9 morbidly obese women following a single intravenous (120 mg) bolus. After the injection, serum elimination conformed to a 2-compartment open model with alpha and beta t1/2s of 0.285 and 2.1 hr. The volume of distribution (Varea) was determined to be 0.44 1/kg ideal body weight (IBW) and 0.20 1/kg total body weight (TBW). To normalize Varea to 0.26 1/kg, 58% of the patients' adipose weight (TBW -- IBW) must also be taken into account.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 487698     DOI: 10.1002/cpt1979264508

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  17 in total

1.  Prediction of Clearance and Volume of Distribution in the Obese from Normal Weight Subjects : An Allometric Approach.

Authors:  Iftekhar Mahmood
Journal:  Clin Pharmacokinet       Date:  2012-08       Impact factor: 6.447

2.  Intravenous Push Administration of Antibiotics: Literature and Considerations.

Authors:  Samantha Spencer; Heather Ipema; Patricia Hartke; Courtney Krueger; Ryan Rodriguez; Alan E Gross; Michael Gabay
Journal:  Hosp Pharm       Date:  2018-03-08

3.  Influence of age on tobramycin pharmacokinetics in patients with normal renal function.

Authors:  L A Bauer; R A Blouin
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

Review 4.  Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics.

Authors:  D T Bearden; K A Rodvold
Journal:  Clin Pharmacokinet       Date:  2000-05       Impact factor: 6.447

Review 5.  What is the best size descriptor to use for pharmacokinetic studies in the obese?

Authors:  Bruce Green; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

Review 6.  Drug disposition in obese humans. An update.

Authors:  D R Abernethy; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

7.  Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients.

Authors:  L A Bauer; W A Edwards; E P Dellinger; D A Simonowitz
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

8.  Vancomycin pharmacokinetics in normal and morbidly obese subjects.

Authors:  R A Blouin; L A Bauer; D D Miller; K E Record; W O Griffen
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

9.  Aminoglycoside dosing weight correction factors for patients of various body sizes.

Authors:  A M Traynor; A N Nafziger; J S Bertino
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

10.  Prediction of the distribution volumes of cefazolin and tobramycin in obese children based on physiological pharmacokinetic concepts.

Authors:  R Koshida; E Nakashima; N Taniguchi; A Tsuji; L Z Benet; F Ichimura
Journal:  Pharm Res       Date:  1989-06       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.